Acute Ischemic Stroke Pipeline Analysis Demonstrates Novel 35+ Companies at the Horizon Expected to Transform the Treatment Paradigm

Acute Ischemic Stroke Pipeline Analysis Demonstrates Novel 35+ Companies at the Horizon Expected to Transform the Treatment Paradigm

DelveInsight’s, “Acute Ischemic Stroke Pipeline Insight, 2023,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in the Acute Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Acute Ischemic Stroke pipeline products in this space.

 

For Acute Ischemic Stroke Emerging drugs, the Acute Ischemic Stroke pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Acute Ischemic Stroke pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Acute Ischemic Stroke Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Acute Ischemic Stroke clinical trials studies, Acute Ischemic Stroke NDA approvals (if any), and product development activities comprising the technology, Acute Ischemic Stroke collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Acute Ischemic Stroke Pipeline Report

 

  • DelveInsight’s Acute Ischemic Stroke pipeline analysis depicts a robust space with 35+ active players working to develop 35+ pipeline treatment therapies.

 

  • The leading Acute Ischemic Stroke Companies include Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, NuvOx Pharma, Healios, Acticor Biotech, Biogen, ZZ Biotech, Revalesio Corporation, Shionogi & Co., Ltd., AbbVie, Pharming Group, Bristol-Myers Squibb, Roche, Clinuvel Pharmaceuticals, TrueBinding, Shin Poong Pharmaceutical, and others.

 

  • Promising Acute Ischemic Stroke Pipeline Therapies include JTR-161, Tirofiban 0.05 MG/ML, YM872 (zonampanel), t-PA (alteplase), Intravenous ACT017 1000 mg, PP-007, Recombinant human urokinase, DLBS1033, Aspirin, Clopidogrel, natalizumab, DS1040b, and others.

 

  • The Acute Ischemic Stroke Companies and academics are working to assess challenges and seek opportunities that could influence Acute Ischemic Stroke R&D. The Acute Ischemic Stroke pipeline therapies under development are focused on novel approaches to treat/improve Acute Ischemic Stroke.

 

Request a sample and discover the recent breakthroughs happening in the Acute Ischemic Stroke Pipeline landscape @ Acute Ischemic Stroke Pipeline Outlook Report

 

Acute Ischemic Stroke Overview

Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, which results in damage to brain cells. Acute ischemic stroke is a leading cause of death and disability in the US and affects approximately 7, 00,000 people each year. Signs and symptoms of stroke may include sudden-onset numbness or weakness in an arm or leg, facial droop, difficulty speaking or understanding speech, confusion, trouble with balance or coordination, and loss of vision.

 

Acute Ischemic Stroke Emerging Drugs Profile

 

  • Nelonemdaz: GNT Pharma

Nelonemdaz is a moderate NR2B-selective N-methyl d-aspartate (NMDA) receptor antagonist and potent spin trapper that reduces NMDA receptor-mediated excitotoxicity and oxidative stress, two major routes of brain cell death leading to disability and death after stroke. Nelonemdaz previously showed better efficacy and a longer therapeutic time window than subtype-unselective NMDA antagonists or antioxidants alone in 5 animal models of stroke. Its safety and tolerability in humans has been established in two earlier phase I studies conducted in 165 healthy young and elderly volunteers in the US and China.

 

  • Tenecteplase: Genentech

Tenecteplase (TNKase, TNK-tPA or TNK) is a thrombolytic agent derived from the tissue plasminogen activator (tPA), that binds fibrin and converts plasminogen to plasmin. It is a 527-amino acid glycoprotein developed by replacing three amino acids at the T, N and K positions of the glycoprotein structure of tPA under genetic recombinant technology. After replacing threonine 103 with asparagine, asparagine 117 with glutamine and a tetra-alanine at amino acids 296–299, TNK is about eightfold more potent in dissolving clot, 80-fold higher resistance to plasminogen activator inhibitor-1 and 14-fold enhanced relative fibrin specificity, and with a longer half-life (20 min).Hence, TNK is administered as a single intravenous bolus. Tenecteplase has a well-characterized mechanism of action with important practical advantages in administration and superior clinical efficacy for patients with large-vessel occlusion. It is currently being evaluated in imaging-eligible, late-window acute ischemic stroke (AIS) patients.

 

  • SP-8203: Shin Poong Pharmaceutical

SP-8203, under development, is a new neuroprotective compound for acute ischemic stroke. It is a quinazoline-2, 4-dione derivative with multiple potent neuroprotective mechanisms of action including anti-inflammatory activities. Patent applications have been filed in 52 countries and granted in 44 countries. SP-8203, has proved as a first-in-class candidate which has a multiple neuroprotective effects through a variety of the stroke animal models. Particularly, because it extends the therapeutic window when combined with tPA, more patients would have the benefit of reducing cerebral infarction and edema as well as hemorrhage and mortality. In fact, a few years following by the project outset, SP-8203 won the top 10 future pharmaceutical special projects run by the Ministry of Health and Welfare, because it was highly evaluated for its distinctiveness. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Acute Ischemic Stroke.

 

  • NONO-SC: NoNO Inc.

NoNO-SC is a subcutaneously injectable nerinetide analog for the treatment of all strokes. Autoinjector compatibility (i.e. a “stroke pen”) enables administration by any caregiver at home, en route to the hospital or upon arrival in the emergency department. Currently, the drug is in Preclinical stage of Clinical trial evaluation for the treatment of Acute Ischemic Stroke.

 

For further information, refer to the detailed Acute Ischemic Stroke Drugs Launch, Acute Ischemic Stroke Developmental Activities, and Acute Ischemic Stroke News, click here for Acute Ischemic Stroke Ongoing Clinical Trial Analysis

 

Acute Ischemic Stroke Pipeline Therapeutics Analysis

There are approx. 35+ key Acute Ischemic Stroke companies which are developing the Acute Ischemic Stroke therapies. The companies which have their Acute Ischemic Stroke drug candidates in the most advanced stage, i.e. phase III include, GNT Pharma.

 

Acute Ischemic Stroke Pipeline Segmentation

 

Phases

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of 
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

  • Intra-articular
  • Intraocular
  • Intrathecal 
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Molecule Type

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Find out more about the Acute Ischemic Stroke Pipeline Segmentation, Therapeutics Assessment, and Acute Ischemic Stroke Emerging Drugs @ Acute Ischemic Stroke Treatment Landscape

 

Scope of the Acute Ischemic Stroke Pipeline Report

 

  • Coverage- Global

 

  • Acute Ischemic Stroke Companies- Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, NuvOx Pharma, Healios, Acticor Biotech, Biogen, ZZ Biotech, Revalesio Corporation, Shionogi & Co., Ltd., AbbVie, Pharming Group, Bristol-Myers Squibb, Roche, Clinuvel Pharmaceuticals, TrueBinding, Shin Poong Pharmaceutical, and others.

 

  • Acute Ischemic Stroke Pipeline Therapies- JTR-161, Tirofiban 0.05 MG/ML, YM872 (zonampanel), t-PA (alteplase), Intravenous ACT017 1000 mg, PP-007, Recombinant human urokinase, DLBS1033, Aspirin, Clopidogrel, natalizumab, DS1040b, and others.

 

  • Acute Ischemic Stroke Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action

 

Dive deep into rich insights for drugs for Acute Ischemic Stroke Pipeline Companies and Therapies, click here @ Acute Ischemic Stroke Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Acute Ischemic Stroke: Overview
  4. Acute Ischemic Stroke Pipeline Therapeutics
  5. Acute Ischemic Stroke Therapeutic Assessment
  6. Acute Ischemic Stroke– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Nelonemdaz: GNT Pharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SP-8203: Shin Poong Pharmaceutical
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name : Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. NONO-SC: NoNO Inc.
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Acute Ischemic Stroke Key Companies
  21. Acute Ischemic Stroke Key Products
  22. Acute Ischemic Stroke Unmet Needs
  23. Acute Ischemic Stroke Market Drivers
  24. Acute Ischemic Stroke Market Barriers
  25. Acute Ischemic Stroke- Future Perspectives and Conclusion
  26. Acute Ischemic Stroke Analyst Views
  27. Acute Ischemic Stroke Key Companies
  28. Appendix

 

Got Queries? Find out the related information on Acute Ischemic Stroke Mergers and acquisitions, Acute Ischemic Stroke Licensing Activities @ Acute Ischemic Stroke Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Posted

in

by

Tags: